open access

Vol 29, No 5 (2022)
Original Article
Submitted: 2021-11-04
Accepted: 2022-05-10
Published online: 2022-06-23
Get Citation

First clinical experience of high-power ablation of atrial fibrillation with a novel contact force-sensing gold-tip catheter

Abdul Shokor Parwani12, Adrian Jayanata1, Robin Kraft1, Philipp Lacour12, Florian Blaschke12, Burkert Pieske12, Leift-Hendrik Boldt12
·
Pubmed: 35762071
·
Cardiol J 2022;29(5):759-765.
Affiliations
  1. Department of Internal Medicine and Cardiology, Charité-Universitätsmedizin Berlin, Campus Virchow Klinikum, Berlin, Germany
  2. DZHK (German Center of Cardiovascular Research), partner site Berlin, Germany

open access

Vol 29, No 5 (2022)
Original articles — Interventional cardiology
Submitted: 2021-11-04
Accepted: 2022-05-10
Published online: 2022-06-23

Abstract

Background: Contact force (CF)-sensing catheters are commonly used in the field of radiofrequency (RF) ablation to treat atrial fibrillation (AF). Increasing ablation power (e.g., 50 W) has been suggested as a method to reduce procedure times whilst creating safe and lasting lesions.

Methods: We report the first clinical evidence of a 50 W point-by-point RF ablation in 25 consecutive patients with symptomatic AF using a novel CF-sensing catheter with a gold tip (AlCath Force, Biotronik). We collected and analyzed procedural and ablation parameters. The safety and efficacy of the catheter were evaluated.

Results: Altogether, 985 RF lesions in 25 patients were created with a mean number of 39.4 ± 16.3 lesions per patient. The total skin-to-skin procedure time was 116.1 ± 35.1 min, and the mean total area dose product was 10.9 ± 5.1 Gy*cm2. The mean RF time per procedure was 13.2 ± 6.6 min. The mean RF time per lesion was 20.2 ± 8.4 s. The mean CF was 15.7 ± 7.6 g. We observed a mean force time integral of 274.7 ± 11.1 gs (range: 53 to 496 gs). Acute procedural success, defined as entrance and exit block in all pulmonary veins, could be obtained in all cases. No procedure- or device-related serious adverse events were observed. No audible steam pops occurred. Optical inspection of the catheter after the procedure showed neither charring nor clotting.

Conclusions: We provide the first evidence for the safety and efficacy of 50 W ablation using the AlCath Force gold-tip catheter. These data must be supported by a larger multi-center study.

Abstract

Background: Contact force (CF)-sensing catheters are commonly used in the field of radiofrequency (RF) ablation to treat atrial fibrillation (AF). Increasing ablation power (e.g., 50 W) has been suggested as a method to reduce procedure times whilst creating safe and lasting lesions.

Methods: We report the first clinical evidence of a 50 W point-by-point RF ablation in 25 consecutive patients with symptomatic AF using a novel CF-sensing catheter with a gold tip (AlCath Force, Biotronik). We collected and analyzed procedural and ablation parameters. The safety and efficacy of the catheter were evaluated.

Results: Altogether, 985 RF lesions in 25 patients were created with a mean number of 39.4 ± 16.3 lesions per patient. The total skin-to-skin procedure time was 116.1 ± 35.1 min, and the mean total area dose product was 10.9 ± 5.1 Gy*cm2. The mean RF time per procedure was 13.2 ± 6.6 min. The mean RF time per lesion was 20.2 ± 8.4 s. The mean CF was 15.7 ± 7.6 g. We observed a mean force time integral of 274.7 ± 11.1 gs (range: 53 to 496 gs). Acute procedural success, defined as entrance and exit block in all pulmonary veins, could be obtained in all cases. No procedure- or device-related serious adverse events were observed. No audible steam pops occurred. Optical inspection of the catheter after the procedure showed neither charring nor clotting.

Conclusions: We provide the first evidence for the safety and efficacy of 50 W ablation using the AlCath Force gold-tip catheter. These data must be supported by a larger multi-center study.

Get Citation

Keywords

ablation, high power, contact force sensing, atrial fibrillation, gold-tip catheter

Supp./Additional Files (1)
Suppl. Figs. 1, 2, 3
Download
369KB
About this article
Title

First clinical experience of high-power ablation of atrial fibrillation with a novel contact force-sensing gold-tip catheter

Journal

Cardiology Journal

Issue

Vol 29, No 5 (2022)

Article type

Original Article

Pages

759-765

Published online

2022-06-23

Page views

4699

Article views/downloads

580

DOI

10.5603/CJ.a2022.0060

Pubmed

35762071

Bibliographic record

Cardiol J 2022;29(5):759-765.

Keywords

ablation
high power
contact force sensing
atrial fibrillation
gold-tip catheter

Authors

Abdul Shokor Parwani
Adrian Jayanata
Robin Kraft
Philipp Lacour
Florian Blaschke
Burkert Pieske
Leift-Hendrik Boldt

References (20)
  1. Kottmaier M, Popa M, Bourier F, et al. Safety and outcome of very high-power short-duration ablation using 70 W for pulmonary vein isolation in patients with paroxysmal atrial fibrillation. Europace. 2020; 22(3): 388–393.
  2. Vassallo F, Cunha C, Serpa E, et al. Comparison of high-power short-duration (HPSD) ablation of atrial fibrillation using a contact force-sensing catheter and conventional technique: Initial results. J Cardiovasc Electrophysiol. 2019; 30(10): 1877–1883.
  3. Castrejón-Castrejón S, Martínez Cossiani M, Ortega Molina M, et al. Feasibility and safety of pulmonary vein isolation by high-power short-duration radiofrequency application: short-term results of the POWER-FAST PILOT study. J Interv Card Electrophysiol. 2020; 57(1): 57–65.
  4. Bourier F, Duchateau J, Vlachos K, et al. High-power short-duration versus standard radiofrequency ablation: Insights on lesion metrics. J Cardiovasc Electrophysiol. 2018; 29(11): 1570–1575.
  5. Kimura M, Sasaki S, Owada S, et al. Comparison of lesion formation between contact force-guided and non-guided circumferential pulmonary vein isolation: a prospective, randomized study. Heart Rhythm. 2014; 11(6): 984–991.
  6. Reddy VY, Shah D, Kautzner J, et al. The relationship between contact force and clinical outcome during radiofrequency catheter ablation of atrial fibrillation in the TOCCATA study. Heart Rhythm. 2012; 9(11): 1789–1795.
  7. Squara F, Latcu DG, Massaad Y, et al. Contact force and force-time integral in atrial radiofrequency ablation predict transmurality of lesions. Europace. 2014; 16(5): 660–667.
  8. le Polain de Waroux JB, Weerasooriya R, Anvardeen K, et al. Low contact force and force-time integral predict early recovery and dormant conduction revealed by adenosine after pulmonary vein isolation. Europace. 2015; 17(6): 877–883.
  9. Yokoyama K, Nakagawa H, Shah DC, et al. Novel contact force sensor incorporated in irrigated radiofrequency ablation catheter predicts lesion size and incidence of steam pop and thrombus. Circ Arrhythm Electrophysiol. 2008; 1(5): 354–362.
  10. Matsuda H, Parwani AS, Attanasio P, et al. Atrial rhythm influences catheter tissue contact during radiofrequency catheter ablation of atrial fibrillation: comparison of contact force between sinus rhythm and atrial fibrillation. Heart Vessels. 2016; 31(9): 1544–1552.
  11. Hohendanner F, Romero I, Blaschke F, et al. Extent and magnitude of low-voltage areas assessed by ultra-high-density electroanatomical mapping correlate with left atrial function. Int J Cardiol. 2018; 272: 108–112.
  12. Eckardt L, Frommeyer G, Sommer P, et al. Updated survey on interventional electrophysiology: 5-year follow-up of infrastructure, procedures, and training positions in Germany. JACC Clin Electrophysiol. 2018; 4(6): 820–827.
  13. Chen J, Dagres N, Hocini M, et al. Catheter ablation for atrial fibrillation: results from the first European Snapshot Survey on Procedural Routines for Atrial Fibrillation Ablation (ESS-PRAFA) Part II. Europace. 2015; 17(11): 1727–1732.
  14. Reddy VY, Dukkipati SR, Neuzil P, et al. Randomized, Controlled Trial of the Safety and Effectiveness of a Contact Force-Sensing Irrigated Catheter for Ablation of Paroxysmal Atrial Fibrillation: Results of the TactiCath Contact Force Ablation Catheter Study for Atrial Fibrillation (TOCCASTAR) Study. Circulation. 2015; 132(10): 907–915.
  15. Mansour M, Calkins H, Osorio J, et al. Persistent Atrial Fibrillation Ablation With Contact Force-Sensing Catheter: The Prospective Multicenter PRECEPT Trial. JACC Clin Electrophysiol. 2020; 6(8): 958–969.
  16. Linhart M, Liberman I, Schrickel JW, et al. Superiority of gold versus platinum irrigated tip catheter ablation of the pulmonary veins and the cavotricuspid isthmus: a randomized study comparing tip temperatures and cooling flow requirements. J Cardiovasc Electrophysiol. 2012; 23(7): 717–721.
  17. Healy SG, Kotschet E, Adam D, et al. P1408Initial experience with a novel contact force sensing system: Results of BIOCONCEPT AlCath Force study. EP Europace. 2017; 19(suppl_3): iii279–iii279.
  18. Enomoto Y, Nakamura K, Ishii R, et al. Lesion size and adjacent tissue damage assessment with high power and short duration radiofrequency ablation: comparison to conventional radiofrequency ablation power setting. Heart Vessels. 2021; 36(9): 1438–1444.
  19. Winkle RA, Mead RH, Engel G, et al. High-power, short-duration atrial fibrillation ablations using contact force sensing catheters: Outcomes and predictors of success including posterior wall isolation. Heart Rhythm. 2020; 17(8): 1223–1231.
  20. Winkle RA, Moskovitz R, Hardwin Mead R, et al. Atrial fibrillation ablation using very short duration 50 W ablations and contact force sensing catheters. J Interv Card Electrophysiol. 2018; 52(1): 1–8.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., Grupa Via Medica, ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl